Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
Coco de Koning(University Medical Center Utrecht), Stefan Nierkens(Utrecht University), Weiyang Tao(Harbin Medical University), Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David Valcárcel(Vall d'Hebron Hospital Universitari), Daniela Cilloni(University of Turin), K. van Veghel(University Medical Center Utrecht), Rabi Hanna(Cleveland Clinic), Caroline A. Lindemans(University Medical Center Utrecht), Guillermo Sanz(Instituto de Salud Carlos III), Einat Galamidi Cohen(Gamida Cell (Israel)), Aridaman Pandit(AbbVie (United States)), Madan Jagasia(Vanderbilt University Medical Center), Amelia M. Lacna(University Medical Center Utrecht), Uri Goshen(Gamida Cell (Israel)), John E. Wagner(Kings County Hospital Center), Jaap Jan Boelens(Wilhelmina Children's Hospital), Tony Peled(Gamida Cell (Israel)), Patrick J. Stiff(Loyola University Medical Center)
Cited by 6
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
|New England Journal of Medicine|2002|986